ArticlePloS one2025
Leveraging transformers and explainable AI for Alzheimer's disease interpretability.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive brain ailment that causes memory loss, cognitive decline, and behavioral changes. It is quite concerning that one in nine adults over the age of 65 have AD. Currently there is almost no cure for AD except very few experimental treatments. However, early detection offers chances to take part in clinical trials or other investigations looking at potential new and effective Alzheimer's treatments. To detect Alzheimer's disease, brain scans such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) can be performed. Many researches have been undertaken to use computer vision on MRI images, and their accuracy ranges from 80-90%, new computer vision algorithms and cutting-edge transformers have the potential to improve this performance.We utilize advanced transformers and computer vision algorithms to enhance diagnostic accuracy, achieving an impressive 99% accuracy in categorizing Alzheimer's disease stages through translating RNA text data and brain MRI images in near-real-time. We integrate the Local Interpretable Model-agnostic Explanations (LIME) explainable AI (XAI) technique to ensure the transformers' acceptance, reliability, and human interpretability. LIME helps identify crucial features in RNA sequences or specific areas in MRI images essential for diagnosing AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.